| abstract |
Described herein are methods for inhibiting Rad51 activity, especially in cancerous cells by the administration of a Rad51 inhibitor. The Rad51 inhibitors described herein are small molecules, preferably smaller than 4kd, including nucelotide diphsophates (selected from the group consisting of ADP, GDP, CDP, UDP and TDP), nucleotide diphosphate complexed with aluminium fluoride (selected from the group consisting of ADP.AIF4, GDP.AIF4, CDP.AIF4, UDP.AIF4 and TDP.AIF4), nucleoside analogues (selected from the group consisiting of ATPyS, GTPyS, UTPyS, CTPyS, TTPyS, ADPyS, GDPyS, UDPyS, CDPyS, TDPyS, AMPyS, GMPyS, UMPyS, CMPyS, TMPyS, ATP-PNP, GTP-PNP, UTP-PNP, CTP-PNP, TTP-PNP, ADP-PNP, GDP-PNP, UDP, PNP, CDP-PNP, TDP-PNP, AMP-PNP, GMP-PNP, UMP-PNP, CMP-PNP and TMP-PNP), DNA minor groove binding agents (selected from the group consisting of distamycin, netropsin, bisbenzimidazole and actinomycin), xanthine derivatives (preferably caffeine), or peptides. |